KalVista Pharmaceuticals (NASDAQ:KALV) issued its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.05, MarketWatch Earnings reports.
Shares of KALV opened at $21.11 on Friday. The stock has a market capitalization of $515.89 million, a P/E ratio of -8.80 and a beta of 1.94. The company’s fifty day moving average is $20.71 and its two-hundred day moving average is $25.33. KalVista Pharmaceuticals has a 1 year low of $12.01 and a 1 year high of $45.00.
Several research firms recently commented on KALV. HC Wainwright reiterated a “buy” rating and issued a $48.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, July 14th. Zacks Investment Research upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $47.43.
A hedge fund recently raised its stake in KalVista Pharmaceuticals stock. Wells Fargo & Company MN increased its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 184.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,307 shares of the specialty pharmaceutical company’s stock after buying an additional 55,998 shares during the period. Wells Fargo & Company MN owned about 0.35% of KalVista Pharmaceuticals worth $2,068,000 as of its most recent SEC filing. Institutional investors and hedge funds own 99.28% of the company’s stock.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Article: Dead Cat Bounce
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.